<div><div></div><div>Cerus reported total revenue of $233.8 million for the year, driven by higher product sales, and disclosed combined cash and short-term investments of $82.9 million. The filing highlights product revenue growth and operational progress across commercialization and clinical programs for its blood safety platforms. Cerus noted ongoing clinical and regulatory activities that support future product rollout and market adoption. Financial Highlights <ul><li>Total revenue: $233.8 million (16% increase versus 2024)</li><li>Product revenue: $206.1 million (14% year-over-year increase)</li><li>Gross Profit: $112.3 million (as reported in summaries)</li><li>Cash &amp; short-term investments: $82.9 million combined ($19.961M cash, $62.918M short-term investments)</li><li>Working capital: $73.2 million</li></ul> Business Highlights <ul><li>Revenue mix and channel dynamics: Growth was primarily driven by higher product sales; Institute for Flow Cytometry (IFC) sales shifted from direct hospital sales toward increased kit sales to blood centers, accelerating demand for kits.</li><li>Commercial momentum: U.S. approvals for platelet, plasma and cryoprecipitation systems support continued market adoption and commercialization of IFC products.</li><li>R&amp;D and regulatory progress: Continued Phase 3 trials (RedeS, ReCePI) and MDR resubmission for the red blood cell system, with additional clinical data expected to inform further regulatory steps.</li><li>Government contracts and development support: BARDA and DoD contracts provided development funding and reimbursement for clinical and scale-up activities, aiding product rollout and commercialization efforts.</li></ul>Original SEC Filing: CERUS CORP [ CERS ] - 10-K - Mar. 02, 2026<section>Disclaimer<div>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</div></section></div></div>

SBIO

IBBQ

CERS

Cerus reported a total revenue of $233.8 million for the year, marking a 16% increase from 2024, driven by higher product sales. Product revenue reached $206.1 million, a 14% year-over-year increase. The company has combined cash and short-term investments of $82.9 million. Key highlights include U.S. approvals for new systems, ongoing clinical trials, and government contracts supporting product rollout and commercialization efforts.

TradingView

ALPS Medical Breakthrough

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

Invesco Nasdaq Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

Cerus

Cerus 10-K: Revenue $233.8M, product growth drives results